Non-therapeutic biomolecules market to reach $56.43 billion by 2030 at 10.7% cagr, driven by rapidly increasing number of research and laboratory testing.
Read More
Non-steroidal anti-inflammatory drugs market to reach $29.96 billion by 2030 at 6.5% cagr, driven by increasing prevalence of musculoskeletal disorders and chronic pain.
Read More
Non-opioid pain treatment market to reach $84.36 billion by 2030 at 8.7% cagr, driven by rising incidence of sports-related injuries.
Read More
Non-opioid pain patch market to reach $4.69 billion by 2030 at 5.5% cagr, driven by rising prevalence of chronic pain.
Read More
Non-injectable insulin market to reach $3.41 billion by 2030 at 9.8% cagr, driven by rising obesity and diabetes issues.
Read More
Non-hormonal contraceptives market to reach $35.8 billion by 2030 at 7.0% cagr, driven by growing prevalence of sexually transmitted diseases.
Read More
Non-alcoholic steatohepatitis treatment market to reach $18.97 billion by 2030 at 39.7% cagr, driven by increased prevalence of insulin resistance.
Read More
Non-alcoholic steatohepatitis (nash) market to reach $24.32 billion by 2030 at 31.9% cagr, driven by rising cases of obesity.
Read More
Non hodgkin lymphoma (nhl) market to reach $16.44 billion by 2030 at 8.8% cagr, driven by high prevalence of non-hodgkin lymphoma.
Read More
Nocturnal enuresis medication market to reach $2.26 billion by 2030 at 6.7% cagr, driven by increasing demand for personalized care and rising healthcare expenditure.
Read More